NCT01141452View on ClinicalTrials.gov

Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD

CompletedOBSERVATIONAL
Enrollment

815,377

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

June 30, 2007

Study Completion Date

July 31, 2007

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Extra-fine hydrofluoroalkane beclomethasone MDI

Step-up in baseline BDP-equivalent ICS dose

DRUG

Chlorofluorocarbon beclomethasone metered dose inhaler

Step-up in baseline BDP-equivalent ICS dose

DRUG

Fluticasone propionate metred dose inhaler

Step-up in baseline BDP-equivalent ICS dose

DRUG

Fluticasone propionate metred dose inhaler

Initiation of ICS therapy

DRUG

Hydrofluoroalkane beclomethasone metred dose inhaler

Initiation of ICS therapy

DRUG

Chlorofluorocarbon beclomethasone dipropionate

Initiation of ICS therapy

Trial Locations (1)

SW8 5NQ

General Practice Research Database, London

All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

Research in Real-Life Ltd

NETWORK

NCT01141452 - Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD | Biotech Hunter | Biotech Hunter